Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) Sees Large Decrease in Short Interest

Tevogen Bio Holdings Inc. (NASDAQ:TVGNW) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 48,900 shares, a decline of 50.4% from the December 31st total of 98,600 shares. Based on an average daily volume of 129,400 shares, the short-interest ratio is presently 0.4 days.

Tevogen Bio Price Performance

TVGNW traded up $0.01 during midday trading on Friday, reaching $0.08. The company’s stock had a trading volume of 225,759 shares, compared to its average volume of 191,693. The stock’s 50-day moving average is $0.06 and its 200-day moving average is $0.04. Tevogen Bio has a 1 year low of $0.01 and a 1 year high of $0.28.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.